A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis

Peer Review reports

Original Submission
9 Jan 2018	Submitted	Original manuscript
8 Feb 2018	Reviewed	Reviewer Report - Tracy Frech
13 Mar 2018	Reviewed	Reviewer Report - John Pauling
21 Mar 2018	Author responded	Author comments - Annemarie Schorpion
Resubmission - Version 2
21 Mar 2018	Submitted	Manuscript version 2
10 Apr 2018	Author responded	Author comments - Annemarie Schorpion
Resubmission - Version 3
10 Apr 2018	Submitted	Manuscript version 3
Publishing
24 Apr 2018	Editorially accepted
15 May 2018	Article published	10.1186/s41927-018-0021-z

Back to article page